Abstract 386P
Background
Wnt/β-catenin pathway is closely related to the development and progression of laryngeal squamous cell carcinoma (LSCC). Loss or reduction of ubiquitination and degradation of β-catenin in cytoplasm result in its accumulation in the nucleus and over-activation of the Wnt/β-catenin pathway. Folate receptor 1 (FRα) is overexpressed in numerous epithelial malignancies. However, the effect of FRα on Wnt/β-catenin pathway and its role in LSCC remains unclear.
Methods
Real-time RT-PCR, Western blot and immunohistochemistry(IHC) detects the mRNA and protein level of FRα in 30 cases of laryngeal squamous cell carcinoma (LSCC) tissues and adjacent normal tissues; Flag-FRα and Si# FRα plasmids were constructed and transfected to establish high FRα expression and low FRα expression cells; EdU assay, colony formation, scratch assay and transwell assay were performed to detect the of proliferation, colony formation, migration and invasion ability of cells; SiRNA#β-catenin was used to block Wnt/β-catenin signal and detected the ability of proliferation, colony formation, migration and invasion; confocal laser detects the subcellular distribution of β-catenin; SgRNA#EGFR was used to silence EGFR signal ; co-immunoprecipitation detects the ubiquitination level of β-catenin.
Results
Q-RT-PCR, WB and IHC showed that the mRNA and protein level of FRα in laryngeal carcinoma tissues was significantly higher than adjacent tissues, and the difference was statistically significant (P<0.01). Compared with FRα low expression (TU177/Flag and TU212/Si-FRα) cells, the proliferation, colony formation, migration and invasion abilities of FRα high expression (TU177/Flag-FRα and TU212/Si-NC) cells were enhanced; SiRNA#β-catenin inhibited FRα -induced cell proliferation, colony formation and migration. Confocal laser results showed that the nuclear accumulation of β-catenin was increased in FRα high expression cells. SgRNA#EGFR inhibited FRα -induced nuclear translocation of β-catenin. Co-immunoprecipitation results displayed that the ubiquitination of β-catenin was decreased in FRα high expression cells.
Conclusions
FOLR1 stabilized β-catenin promotes laryngeal carcinoma progression through EGFR signa.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
H.Tuo.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract